Unknown OBSERVATIONAL NCT05812612

UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease

Study on the Treatment of COVID-19 Infection by UDCA in Patients With Autoimmune Liver Disease and Its Clinical Prognosis

Sponsor: Beijing Ditan Hospital

Conditions COVID-19 Infection

Interventions ursodeoxycholic acid

Updated 4 times since 2023 Last updated: Apr 11, 2023 Started: Jan 30, 2023 Primary completion: Dec 30, 2023 Completion: Dec 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on COVID-19 Infection, this trial is ongoing. The trial is conducted by Beijing Ditan Hospital and has accumulated 4 data snapshots since 2023. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

4 versions recorded

May 2025 — Present [monthly]

Unknown

Status: Recruiting → Unknown
Sep 2024 — May 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
May 2023 — Jul 2024 [monthly]

Recruiting

First recorded

Jan 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Ditan Hospital

Data source: Beijing Ditan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China